Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer
Peter Fasching • 1 Jun 2018
Which NSCLC patients should receive chemotherapy and anti-angiogenics?
Marina Garassino • 11 Apr 2018